ReviewInternational journal of molecular sciences2024
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial.International journal of hematology · 2026Trial
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials.Therapeutic innovation & regulatory science · 2026Article
- Identification of exhausted CD8Translational cancer research · 2026Article
- Review
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- Single-cell RNA sequencing analysis revealed a potential association between ELK3 expression and the progression of multiple myeloma.Frontiers in immunology · 2026Article
- Recent Updates and Advancements in the Diagnosis and Management of Plasma Cell Dyscrasias.Cureus · 2026Review
- CyTOF profiling of bone marrow immune dynamics across myeloma stages.Oncoimmunology · 2025Article
- Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.British journal of haematology · 2025Review
- Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review.Annals of hematology · 2025Review
- Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.Balkan medical journal · 2025Review
- An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma.International journal of molecular sciences · 2025Article
- Visfatin promotes multiple myeloma cell proliferation and inhibits apoptosis by inducing IL-6 production via NF-κB pathways.Discover oncology · 2025Article
- Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.Cancer medicine · 2025Review
- Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region.Clinical hematology international · 2025Review
- Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region.Clinical hematology international · 2025Review
- PPIH Expression Correlates with Tumor Aggressiveness and Immune Dysregulation in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal dysfunction, infection, bone pain, hypercalcemia, and fatigue. Despite numerous recent advancements in the MM treatment paradigm, current therapies demonstrate limited long-term effectiveness and eventual disease relapse remains exceedingly common. Myeloma cells often develop drug resistance through clonal evolution and alterations of cellular signaling pathways. Therefore, continued research of new targets in MM is crucial to circumvent cumulative drug resistance, overcome treatment-limiting toxicities, and improve outcomes in this incurable disease. This article provides a comprehensive overview of the landscape of novel treatments and emerging therapies for MM grouped by molecular target. Molecular targets outlined include BCMA, GPRC5D, FcRH5, CD38, SLAMF7, BCL-2, kinesin spindle protein, protein disulfide isomerase 1, peptidylprolyl isomerase A, Sec61 translocon, and cyclin-dependent kinase 6. Immunomodulatory drugs, NK cell therapy, and proteolysis-targeting chimera are described as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.